AmoyDx and Premia will provide large-scale cancer patient screening in Asia to support Loxo-292 RET inhibitor clinical development.
The NGS assay is designed to help physicians to identify non-small cell lung cancer patients who may benefit from eight targeted therapies.
Researchers will first compare liquid with tissue-based tumor profiling before implementing it as a way to enroll patients into the targeted drug trials.
AmoyDx's kit is designed to detect hotspot mutations/fusions in nine genes to help guide treatment decisions for non-small cell lung cancer patients.
The assay can identify KRAS, NRAS, PIK3CA, BRAF, and EGFR gene mutations, as well as 19 gene rearrangements of the ALK, ROS1, RET, NTRK1, and MET genes from FFPE.
The companies will develop a version of Illumina's TruSight 170 sequencing panel for two of Loxo's targeted oncology drugs.
Originally published March 25.
The European Commission has approved Cometriq (cabozantinib) as a treatment for medullary thyroid cancer (MTC) patients.
Originally published Nov. 29.
By Turna Ray
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.